Nurexone says exosomes beat industry healing standard

Executive Summary

• Nurexone Biologic Inc. released results from an independent study conducted by TAmiRNA GmbH, demonstrating that its proprietary exosomes outperform a recognized commercial industry standard in key healing tasks, including nerve repair, wound repair, immune system modulation, and tissue rebuilding.
• The study indicates that Nurexone's "naive exosomes" deliver more than twice the wound-healing signals compared to the industry benchmark, highlighting potential applications in aesthetic skin rejuvenation, wound care, and orthopedic tissue repair.
• The data provides third-party validation of Nurexone's core technology, specifically its proprietary master cell bank and patent-pending 3-D production process, which ensures reproducibility and high performance for clinical translation and future commercial partnerships.

Key Details

• Study Performer: TAmiRNA GmbH, an ISO13485-certified molecular-diagnostics laboratory.
• Comparison Benchmark: A commercial reference source of exosomes.
• Key Finding - Wound Healing: Nurexone's exosomes deliver more than twice the wound-healing signals compared to the industry benchmark.
• Key Finding - Therapeutic Potential: Exosomes are enriched with microRNAs supporting neuroprotection, reduction in inflammation, and nerve regeneration.
• Production Method: Exosomes are produced from Nurexone's proprietary master cell bank under rigorously controlled environments to ensure batch-to-batch reproducibility.
• Strategic Context: The data supports the manufacturing capabilities of Nurexone's U.S. subsidiary, ExoTOP Inc., which is scaling production using a patent-pending 3-D process to generate revenue streams and supply partners in regenerative medicine.
• Company Focus: Nurexone is focused on regenerative exosome-based therapies for central nervous system injuries, with lead product ExoPTEN showing preclinical potential for acute spinal cord and optic nerve injury.

Notable Quotes

• "This data confirms that the naive exosomes that will be manufactured by our U.S. subsidiary, ExoTOP Inc. (ExoTOP), will carry a strong regenerative and therapeutic punch. Delivering more than twice the wound-healing signals than the industry benchmark suggests applications in aesthetic skin rejuvenation, wound care and orthopedic tissue repair." — Jacob Licht, CEO of ExoTOP
• "Our exosomes carry complex cargo with diverse therapeutic potential, simultaneously being effective in neuroprotection and reduction in inflammation... The benchmarking analysis confirms that our exosomes naturally carry a significant amount of the molecular signals needed to create the conditions required for meaningful nerve regeneration." — Dr. Tali Kizhner, Director of Research and Development of Nurexone Biologic